CWA Asset Management Group LLC Has $6.08 Million Position in Gilead Sciences, Inc. $GILD

CWA Asset Management Group LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,812 shares of the biopharmaceutical company’s stock after selling 10,931 shares during the period. CWA Asset Management Group LLC’s holdings in Gilead Sciences were worth $6,084,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of GILD. GoalVest Advisory LLC grew its holdings in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences in the second quarter valued at about $27,000. Putney Financial Group LLC grew its stake in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the last quarter. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences during the second quarter worth approximately $30,000. Finally, Kilter Group LLC acquired a new stake in shares of Gilead Sciences during the second quarter worth approximately $33,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the sale, the insider owned 106,221 shares in the company, valued at approximately $12,958,962. The trade was a 2.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at $1,115,713.60. This represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 136,257 shares of company stock worth $16,855,192. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on GILD shares. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Wells Fargo & Company raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Argus upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, BMO Capital Markets set a $135.00 price objective on shares of Gilead Sciences in a report on Tuesday, November 25th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $131.68.

Gilead Sciences Price Performance

Shares of GILD stock opened at $121.60 on Monday. The stock has a 50-day moving average price of $123.05 and a 200 day moving average price of $117.17. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm has a market cap of $150.87 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 0.65 and a beta of 0.33. Gilead Sciences, Inc. has a 12 month low of $88.57 and a 12 month high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. During the same period in the prior year, the company posted $2.02 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.